Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence80
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma76
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?41
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia40
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review35
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma30
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects30
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence28
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs28
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer27
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review27
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis25
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma24
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma23
Progress in the development of tissue-based biomarkers for urothelial cancer23
Current status and novel insights into the role of metastasectomy in the era of immunotherapy22
Current management of familial adenomatous polyposis22
Progress in histology specific treatments in soft tissue sarcoma21
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer21
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan21
0.086047887802124